Skip to content

Study · Non-randomized trial · n = 24 · 1994

2 results

Palliation of malignant intestinal obstruction using octreotide.

Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J

European journal of cancer (Oxford, England : 1990)1 Jan 1994Cited by 51 (Europe PMC)

PMID7511400 (opens in a new tab)DOI10.1016/s0959-8049(05)80012-7 (opens in a new tab)PepBankPUB-07511400
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In malignant intestinal obstruction, octreotide controlled vomiting or markedly reduced nasogastric aspirate in 18 of 24 (75%) patients.

    In plain wordsIn patients with malignant intestinal obstruction, octreotide controlled vomiting or markedly reduced stomach drainage in 75%.

    Peptide
    Octreotide
    Outcome
    DecreaseVomiting control or aspirate reduction
    Study

    n = 24

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    median initial 300, range 100-600 micrograms/day · subcutaneous infusion · median 9.4, range 1-38 daysAs given in this study (human).

    Measurements

    Patients with vomiting controlled or aspirate markedly reduced
    18 of 24 patients
    octreotide
    Response rate
    75 percent
    octreotide

    Source sentences

    Summary
    Vomiting was controlled or the volume of nasogastric aspirate was markedly reduced in 18 of 24 (75%) patients receiving a subcutaneous infusion of octreotide (median initial dose 300, range 100-600 micrograms/day) for a median of 9.4 (range 1-38) days.
    1 context sentence
    Summary · context
    For this reason, octreotide was used in a phase I/II study of patients with intractable vomiting secondary to intestinal obstruction due to malignant disease.
  2. 02HumanNon-randomized trialEfficacy outcome

    In malignant intestinal obstruction, two further octreotide-treated patients had partial symptom relief.

    In plain wordsIn patients with malignant intestinal obstruction, two further patients had partial symptom relief with octreotide.

    Peptide
    Octreotide
    Outcome
    DecreasePartial symptom relief
    Study

    n = 24

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    median initial 300, range 100-600 micrograms/day · subcutaneous infusion · median 9.4, range 1-38 daysAs given in this study (human).

    Measurements

    Patients with partial relief of symptoms
    2 patients
    octreotide

    Source sentences

    Summary
    A further 2 patients had partial relief of their symptoms.
    1 context sentence
    Summary · context
    For this reason, octreotide was used in a phase I/II study of patients with intractable vomiting secondary to intestinal obstruction due to malignant disease.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.